Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | OPRD1 | P41143 | 13/20 | 0.40 |
| ▸ | KCNH2 | Q12809 | 8/20 | 0.40 |
| ▸ | OPRM1 | P35372 | 7/20 | 0.40 |
| ▸ | SRPK1 | Q96SB4 | 3/20 | 0.39 |
| ▸ | DRD2 | P14416 | 1/20 | 0.37 |
| ▸ | FNTA | P49354 | 1/20 | 0.37 |
| ▸ | FNTB | P49356 | 1/20 | 0.37 |
| ▸ | GPR6 | P46095 | 1/20 | 0.37 |
| ▸ | AURKA | O14965 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2733434 | 0.80 | CHRM2 (0.44) | OPRD1KCNH2OPRM1SRPK1 | |
| SCHEMBL28872036 | 0.74 | TSHR (0.51) | — | |
| SCHEMBL210366 | 0.74 | OPRD1 (0.42) | OPRD1KCNH2OPRM1SRPK1DRD2 | |
| SCHEMBL14338849 | 0.73 | KCNH2 (0.49) | OPRD1KCNH2OPRM1DRD2AURKA | |
| SCHEMBL23028550 | 0.71 | CKS1B (0.47) | DRD2FNTAFNTB | |
| SCHEMBL31546371 | 0.70 | LTA4H (0.50) | OPRD1KCNH2OPRM1DRD2 | |
| SCHEMBL28831464 | 0.69 | L3MBTL1 (0.45) | DRD2 | |
| SCHEMBL21612153 | 0.69 | PPARG (0.35) | KCNH2 | |
| SCHEMBL2662022 | 0.68 | CHKA (0.47) | OPRD1KCNH2OPRM1DRD2 | |
| SCHEMBL28872094 | 0.68 | KMT2A (0.52) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-109563092-A | It can be used as the 2- phenylimidazole of the active inhibitor of mammal tyrosine kinase ROR1 simultaneously [4,5-B] pyridine -7- amine derivative | 坎塞拉有限公司 | 2019-04-02 | — | — | CN | disclosed |